{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:43:10Z","timestamp":1789706590937,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jaad.2019.12.038","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T12:26:58Z","timestamp":1577363218000},"page":"1138-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16\u00a0weeks: Results from a network meta-analysis"],"prefix":"10.1016","volume":"82","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Huayu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Brnabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.12.038_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000350008","article-title":"Cumulative life course impairment: evidence for psoriasis","volume":"44","author":"Mattei","year":"2013","journal-title":"Curr Probl Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.12.038_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/09546634.2017.1329499","article-title":"What is clearance worth? Patients' stated risk tolerance for psoriasis treatments","volume":"28","author":"Fairchild","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"10.1016\/j.jaad.2019.12.038_bib3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/jdv.14211","article-title":"Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3","volume":"31","author":"Leonardi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.12.038_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2003.307","article-title":"Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis","volume":"48","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.038_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"Supp. 1","key":"10.1016\/j.jaad.2019.12.038_bib6","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1046\/j.1525-1497.1999.00267.x","article-title":"The doctor-patient relationship","volume":"14","author":"Goold","year":"1999","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/09546634.2016.1214667","article-title":"Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis","volume":"28","author":"Armstrong","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.12.038_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.wndm.2013.06.001","article-title":"Cumulative Life Course Impairment (CLCI): a new concept to characterize persistent patient burden in chronic wounds","volume":"1","author":"Augustin","year":"2013","journal-title":"Wound Med"},{"key":"10.1016\/j.jaad.2019.12.038_bib10","series-title":"Taltz [prescribing information]. Indianapolis, IN: Eli Lilly and Company","year":"2016"},{"key":"10.1016\/j.jaad.2019.12.038_bib11","series-title":"Taltz: EPAR summary for the public","year":"2016"},{"key":"10.1016\/j.jaad.2019.12.038_bib12","series-title":"Cosentyx [prescribing information]","year":"2018"},{"key":"10.1016\/j.jaad.2019.12.038_bib13","series-title":"Siliq [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaad.2019.12.038_bib14","series-title":"Tremfya [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaad.2019.12.038_bib15","series-title":"Ilumya [prescribing information]","year":"2018"},{"key":"10.1016\/j.jaad.2019.12.038_bib16","series-title":"Stelara [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaad.2019.12.038_bib17","series-title":"Humira [prescribing information]","year":"2011"},{"key":"10.1016\/j.jaad.2019.12.038_bib18","series-title":"Remicade [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaad.2019.12.038_bib19","series-title":"Enbrel [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaad.2019.12.038_bib20","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0","year":"2011"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.038_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.12.038_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2019.12.038_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bjd.16426","article-title":"Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P)","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.038_bib25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.12.038_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.038_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.12.038_bib29","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.038_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2019.12.038_bib31","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.038_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"9625","key":"10.1016\/j.jaad.2019.12.038_bib33","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.jaad.2019.12.038_bib34","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10091","key":"10.1016\/j.jaad.2019.12.038_bib39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.038_bib40","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.12.038_bib42","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.038_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2019.12.038_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.jaad.2019.12.038_bib45","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2019.12.038_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jaad.2019.12.038_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"Alternative methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"10.1016\/j.jaad.2019.12.038_bib48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjd.13437","article-title":"Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response","volume":"172","author":"Signorovitch","year":"2015","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2019.12.038_bib49","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis","volume":"137","author":"Jabbar-Lopez","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.12.038_bib50","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjd.14814","article-title":"Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"176","author":"G\u00f3mez-Garc\u00eda","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.12.038_bib51","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/2013.jamadermatol.238","article-title":"Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a Bayesian network meta-analysis","volume":"148","author":"Lin","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2019.12.038_bib52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000233234","article-title":"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis","volume":"219","author":"Bansback","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.12.038_bib53","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2019.12.038_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2018.1427205","article-title":"The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis","volume":"29","author":"Sawyer","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2019.12.038_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","article-title":"Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course","volume":"164","author":"Warren","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.038_bib56","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ad.2013.02.009","article-title":"Cumulative life course impairment: the imprint of psoriasis on the patient's life","volume":"105","author":"Ros","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaad.2019.12.038_bib57","series-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias","year":"2011"},{"issue":"2","key":"10.1016\/j.jaad.2019.12.038_bib58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mpr.1381","article-title":"Critical evaluation of mixed treatment comparison meta-analyses using examples assessing antidepressants and opioid detoxification treatments","volume":"22","author":"Schacht","year":"2013","journal-title":"Int J Methods Psychiatr Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219333158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219333158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:53:49Z","timestamp":1759272829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219333158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0190962219333158"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.038","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16\u00a0weeks: Results from a network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}